Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04124406 · ClinicalTrials.gov registry record
Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality
A clinical trial of Colon Cancer, sponsored by Exact Sciences Corporation.
- Active
- Registry status
- 150,000
- Enrollment target
- 1
- Study location
NCT04124406 is a study of Colon Cancer that is active but no longer recruiting, run by Exact Sciences Corporation. The registered enrollment target is 150,000 participants, above the 2,910-participant average among 97 other Colon Cancer trials with a reported enrollment target (5055% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04124406, a study of Colon Cancer, is active but no longer recruiting, sponsored by Exact Sciences Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- 150,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to gather information about the long term health of people who have been prescribed the Cologuard test, which is used for colorectal cancer (CRC) screening.
Conditions Studied
Interventions
- DEVICE Cologuard
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150,000 participants |
| Start Date | 2019-10-18 |
| Est. Completion | 2025-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04124406
The ClinicalTrials.gov registry entry for NCT04124406 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 150,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,910-participant average among 97 other Colon Cancer trials with a reported enrollment target (5055% higher). The listed sponsor is Exact Sciences Corporation, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cologuard is the first listed.
NCT04124406 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04124406 about?
NCT04124406 is a clinical study titled "Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality". The purpose of this study is to gather information about the long term health of people who have been prescribed the Cologuard test, which is used for colorectal cancer (CRC) screening.
What is the current status of trial NCT04124406?
This trial is currently active not recruiting. The enrollment target is 150,000 participants. The study started on 2019-10-18. Estimated completion is 2025-12.
What conditions does trial NCT04124406 study?
This clinical trial studies the following conditions: Colon Cancer.
What interventions are being tested in trial NCT04124406?
The interventions under investigation include: Cologuard (DEVICE).
Who is sponsoring clinical trial NCT04124406?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04124406 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
-
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.